Effect of fish oil on arrhythmias and mortality: systematic review
- PMID: 19106137
- PMCID: PMC2612582
- DOI: 10.1136/bmj.a2931
Effect of fish oil on arrhythmias and mortality: systematic review
Abstract
Objective: To synthesise the literature on the effects of fish oil-docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)-on mortality and arrhythmias and to explore dose response and formulation effects.
Design: Systematic review and meta-analysis.
Data sources: Medline, Embase, the Cochrane Library, PubMed, CINAHL, IPA, Web of Science, Scopus, Pascal, Allied and Complementary Medicine, Academic OneFile, ProQuest Dissertations and Theses, Evidence-Based Complementary Medicine, and LILACS. Studies reviewed Randomised controlled trials of fish oil as dietary supplements in humans.
Data extraction: The primary outcomes of interest were the arrhythmic end points of appropriate implantable cardiac defibrillator intervention and sudden cardiac death. The secondary outcomes were all cause mortality and death from cardiac causes. Subgroup analyses included the effect of formulations of EPA and DHA on death from cardiac causes and effects of fish oil in patients with coronary artery disease or myocardial infarction.
Data synthesis: 12 studies totalling 32 779 patients met the inclusion criteria. A neutral effect was reported in three studies (n=1148) for appropriate implantable cardiac defibrillator intervention (odds ratio 0.90, 95% confidence interval 0.55 to 1.46) and in six studies (n=31 111) for sudden cardiac death (0.81, 0.52 to 1.25). 11 studies (n=32 439 and n=32 519) provided data on the effects of fish oil on all cause mortality (0.92, 0.82 to 1.03) and a reduction in deaths from cardiac causes (0.80, 0.69 to 0.92). The dose-response relation for DHA and EPA on reduction in deaths from cardiac causes was not significant.
Conclusions: Fish oil supplementation was associated with a significant reduction in deaths from cardiac causes but had no effect on arrhythmias or all cause mortality. Evidence to recommend an optimal formulation of EPA or DHA to reduce these outcomes is insufficient. Fish oils are a heterogeneous product, and the optimal formulations for DHA and EPA remain unclear.
Conflict of interest statement
Competing interests: None declared.
Figures
Comment in
-
Fish oil and secondary prevention of cardiovascular disease.BMJ. 2008 Dec 23;337:a2541. doi: 10.1136/bmj.a2541. BMJ. 2008. PMID: 19106136 No abstract available.
-
Fish oil and arrhythmias. Pro-arrhythmic effects of fish oils.BMJ. 2009 Feb 2;338:b393. doi: 10.1136/bmj.b393. BMJ. 2009. PMID: 19188223 No abstract available.
References
-
- Bang HO, Dyerberg J, Hjoorne N. The composition of food consumed by Greenland eskimos. Acta Med Scand 1976;200:69-73. - PubMed
-
- McLennan PL. Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models. Lipids 2001;36(suppl):S111-4. - PubMed
-
- Charnock JS, Abeywardena MY, Poletti VM, McLennan PL. Differences in fatty acid composition of various tissues of the marmoset monkey (Callithrix jacchus) after different lipid supplemented diets. Comp Biochem Physiol Comp Physiol 1992;101:387-93. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous